ArticleUrolithiasis2025
Unraveling the gut-immune-kidney axis in kidney stone disease: a two-step Mendelian randomization investigation.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiota: a novel key player in urinary stone formation - from oxalate metabolism to systemic regulation.Gut microbes · 2026Review
- Multi-habitat microbiome profiling identifies habitat-dependent alterations and complementary discriminatory information in urolithiasis.Frontiers in cellular and infection microbiology · 2026Article
- Paradigm shift in kidney stone research: moving beyond metabolism toward the gut-immune-kidney axis.Urolithiasis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota (GM) is increasingly acknowledged for its regulatory role in host immune responses and its influence on various systemic diseases. Nevertheless, whether GM modulates kidney stone disease (KSD) through immune-related mechanisms remains uncertain. To investigate these associations, we conducted Mendelian randomization (MR) analyses in two sequential steps, employing summary-level data sourced from comprehensive genome-wide association studies (GWAS). Specifically, the potential causal influence of 430 GM features on 731 immune-cell-related traits, and subsequently their effects on KSD susceptibility, was assessed. The primary analysis utilized the inverse variance weighted (IVW) method, alongside complementary approaches including MR-Egger regression, weighted median analysis, and various sensitivity evaluations. Moreover, a mediation MR analysis was conducted to determine if specific immune cell subsets mediated relationships between GM and KSD. Our analysis revealed significant causal associations between 15 GM taxa and KSD. Protective effects were observed for genera such as Prevotella, Phascolarctobacterium, and Ruminococcaceae, whereas elevated risks of KSD were associated with Bacteroides, Clostridiales, and Subdoligranulum. Furthermore, 35 immune-cell-related phenotypes displayed causal links to KSD risk. Importantly, CD28 expression on CD39 + CD4 + T cells was identified as a mediator in the protective pathway from Prevotella to KSD, with a mediation effect estimated at -9.019% (P = 0.044). No significant directional pleiotropy or heterogeneity was observed. These findings provide novel causal evidence supporting the existence of a gut-immune-kidney axis, where certain gut microbes influence KSD susceptibility via immune mechanisms. This may guide the development of microbiota- or immune-targeted strategies for the prevention of KSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.